XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has refiled its management’s discussion and analysis (“MD&A”) for the financial year ended December 31, 2023 and for the interim period ended June 30, 2024 as a result of a continuous disclosure review by the Alberta Securities Commission.
The originally filed MD&A for the financial year ended December 31, 2023 included an abbreviated definition of Disclosure Controls and Procedures under the section Internal Controls Over Financial Reporting.
The amended MD&A for the financial year ended December 31, 2023 includes the full definition of Disclosure Controls and Procedures as provided in NI 52-109. Additional information in the amended MD&A for the interim period ended June 30, 2024 includes a breakdown of use of funds for the Company’s product candidates under the section Funding Requirements and Future Plans and estimated costs in the Outlook section.
Other than as set forth above, both the amended MD&A for the financial year ended December 31, 2023 and for the interim period ended June 30, 2024 does not purport to, update or restate the information from the originally filed MD&A documents or reflect any events that occurred after the date of the filing of the original MD&A documents.
The amended MD&A documents are both restated as of September 12, 2024 and they should be read in conjunction with the Company’s financial statements for the corresponding period, including the accompanying notes.
The amended MD&A documents have been reviewed by the Company’s Audit Committee and approved by the Company’s Board of Directors as of September 12, 2024.
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection.
In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid.
At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX is available at www.xortx.com.
care of the redaction
please follow us also on Instagram: nome utente: gio.vanni.acerbi
